GTF2B and hepatocellular carcinoma: Tu and Tang (2004) studied the effects of TFs, TFDG, and theaflavin‐3‐gallate (TF2B) on gastric carcinoma (MKN‐288), hepatoma (BEL‐7402), and leukemia (LH‐60) cells and found significant inhibitory effects of TF2B on all three cells, while the inhibitory effect of TFDG on MKN‐288 and BEL‐7402 cells was higher than that of TFs.